Skip to main navigation

Top

Skip to main content

About Us

About Us
Genetically Defined Diseases

Genetically Defined Diseases
Pipeline

Pipeline
Patients & Partners

Patients & Partners
Investors

Investors
Inside Agios

Inside Agios

Press Releases

Investors Overview
News & Events
Stock Information
Corporate Governance
Financials
IR Resources

Year

Sep 26, 2022

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Read More

PDF Version

Sep 19, 2022

Agios Appoints Cecilia Jones as Chief Financial Officer

Read More

PDF Version

Sep 16, 2022

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Read More

PDF Version

Aug 24, 2022

Agios to Participate in September Investor Conferences

Read More

PDF Version

Aug 18, 2022

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

Read More

PDF Version

Aug 15, 2022

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Read More

PDF Version

Aug 11, 2022

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

Read More

PDF Version

Aug 08, 2022

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

Read More

PDF Version

Aug 04, 2022

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

Read More

PDF Version

Jul 14, 2022

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

Read More

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 23

Latest Earnings Call View Replay
Latest Form 10-K View PDF
Email Alerts Sign Up
Corporate Fact Sheet View PDF
Corporate Responsibility View PDF

Connect with us on LinkedIn or follow us on Twitter as we push forward into changing the landscape for people with genetically defined diseases.

Connect on LinkedIn

Follow us our Twitter

Contact
About Us
Patients & Partners
Careers

Agios Pharmaceuticals, Inc. © 2022

All right reserved.

Cookies Preferences
Copyright Info
Compliance
Sitemap
Privacy Notice
Terms of Use